TNF and metabolic syndrome: Although in a study that included RA patients with severe disease undergoing anti-TNF-α infliximab therapy, visfatin levels were not associated with inflammation or metabolic syndrome and infliximab infusion did not show significant changes in visfatin levels [151], another study showed that prolonged anti- TNF-α treatment may reduce visfatin levels [151, 152].